ImClone's (IMCL) Carl Icahn Issues Statement On Takeover Bid
More News related to BMY
- Exelixis and Bristol-Myers Squibb to Co-Develop XL413, a Selective Cdc7 Inhibitor
- Bristol-Myers Squibb to Present at Healthcare Conference
- Tekmira Pharmaceuticals Corporation Announces Third Quarter 2008 Operating Results and Provides Program Update
- Athersys Announces Clinical Development Milestone in Bristol-Myers Squibb Discovery Alliance
- Notable Analyst Rating Changes 11/07: ANF, TWTC, CECEO Upgraded; TM, DLB, SI Downgraded
More News related to IMCL
- NASDAQ OMX and Leerink Swann to Co-Host Healthcare Industry Forum
- Lilly Completes Cash Tender Offer for ImClone Systems
- ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
- Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
- ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
More News related to LLY
- Eli Lilly (LLY) Withdraws NDA for Cymbalta for Treatment of Chronic Pain
- Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
- Eli Lilly (LLY) Completes Acquisition of ImClone Systems
- Lilly Completes Acquisition of ImClone Systems
- Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
More News related to Rumors
- Sources Say 'Highly Unlikely' That Miller Buys Yahoo! (YHOO) -CNBC
- Reports Former AOL CEO Raising Money For Yahoo! (YHOO) Deal
- Former AOL CEO John Miller In Talks With PE Shops To Buy Yahoo (YHOO)
- Reports Total Is Preparing A Bid For NEXEN (NXY)
- NEXEN (NXY) Pops On Buyout Talk
ImClone Systems (Nasdaq: IMCL) Chairman Carl Icahn issued a statement regarding a potential buyout of the company.
Icahn said, "the large Pharma company has completed due diligence and made a proposal not subject to financing or further due diligence. Negotiations between the parties are underway and the large Pharma company has requested that ImClone not divulge its name until negotiations are completed."
Yesterday, it was reported that Eli Lilly (NYSE: LLY) was the mystery bidder. ImClone has resisted overtures from partner Bristol-Myers (NYSE: BMY) in lieu of the competing bid. Bristol-Myers recently raised its bid to $62, but Eli Lilly's bid is said to be $70 per share.
Related Categories
Mergers and AcquisitionsRumors
Stocks Mentioned
+0.92Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
